Trial Profile
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin
- Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacodynamics
- Acronyms INTENSITY-LOW
- 07 Jan 2020 Status changed from recruiting to completed.
- 08 Sep 2017 New trial record
- 07 Sep 2017 Status changed from not yet recruiting to recruiting.